GlassScriptPhysician profile
Rae J Jessee
NPI 1154316065
$3,340.70
in general payments reported to CMS, 2019-2025
27 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $726 · 2022: $513 · 2023: $539 · 2024: $462 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Food and Beverage: $831 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Food and Beverage | $831.48 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,100.00 | 2025 | Omnipod |
| Abbvie INC. | $540.79 | 2021-2024 | |
| Lilly USA, LLC | $286.24 | 2021-2024 | Mounjaro |
| Medtronic, INC. | $187.20 | 2021-2024 | Minimed 780g |
| Glaxosmithkline, LLC. | $162.31 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $148.44 | 2023 | Korlym |
| Amgen INC. | $118.86 | 2021-2024 | Repatha, Otezla |
| Novo Nordisk INC | $108.23 | 2021-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $84.76 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.38 | 2021-2023 | |
| Mannkind Corporation | $73.41 | 2021-2022 | |
| Esperion Therapeutics, INC. | $71.18 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $55.46 | 2021-2024 | Gvoke Hypopen |
| Pfizer INC. | $53.81 | 2021-2022 | |
| Ibsa Pharma INC. | $43.92 | 2021-2024 | Tirosint, Tirosint, Licart |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.11 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $34.74 | 2023 | Rexulti |
| Astellas Pharma US INC | $30.96 | 2021-2023 | Veozah |
| Smith+Nephew, INC. | $16.15 | 2021 | |
| Allergan, INC. | $16.07 | 2021 | |
| Qol Medical, LLC | $16.04 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $14.96 | 2021 | |
| Amryt Pharma Holdings LTD | $14.67 | 2021 | |
| Abbott Laboratories | $14.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.87 | 2021 | |
| Beta Bionics, INC. | $10.44 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rae Jessee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.